Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Başak Dalkili�
Partial Agonistic Effect of Cetuximab on Epidermal Growth Factor Receptor and SRC Kinase Activation in Triple‑negative Breast Cancer Cell Lines
International Journal of Oncology
Cancer Research
Oncology
Related publications
The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
Bulletin of Siberian Medicine
Molecular Medicine
Role of Epidermal Growth Factor Receptor in Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
Estrogen Receptor Β1 Activation Accelerates Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Oncology Reports
Medicine
Cancer Research
Oncology
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
JAMA - Journal of the American Medical Association
Medicine
Down-Regulation of Cathepsin S and Matrix Metalloproteinase-9 via Src, a Non-Receptor Tyrosine Kinase, Suppresses Triple-Negative Breast Cancer Growth and Metastasis
Experimental & Molecular Medicine
Midostaurin Preferentially Attenuates Proliferation of Triple-Negative Breast Cancer Cell Lines Through Inhibition of Aurora Kinase Family
Journal of Biomedical Science
Cell Biology
Pharmacology
Biochemistry
Endocrinology
Clinical Biochemistry
Molecular Biology
Medicine
Metabolism
Diabetes
Epidermal Growth Factor Stimulates Rac Activation Through SRC and Phosphatidylinositol 3-Kinase to Promote Colonic Epithelial Cell Migration
American Journal of Physiology - Gastrointestinal and Liver Physiology
Hepatology
Physiology
Gastroenterology
Cisplatin in Combination With Zoledronic Acid: A Synergistic Effect in Triple-Negative Breast Cancer Cell Lines
International Journal of Oncology
Cancer Research
Oncology
Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast Cancer
